India & World UpdatesHappeningsBreaking News

No more communication gap; Patanjali has 100% fulfilled all standard parameters for ‘Coronil’!

June 24: Hours after the AYUSH Ministry asked yoga guru Ramdev’s Patanjali Ayurveda to provide the details of the medicine it claimed is for the treatment of COVID-19, Patanjali CEO Acharya Balkrishna issued a statement, where he stated that the communication gap has been done away with and his company has 100% fulfilled all standard parameters for Randomised Placebo-Controlled Clinical Trials. Earlier, the AYUSH Ministry asked Patanjali to stop advertising the product until the “issue is examined.”

Acharya Balkrishna of Patanjali in a tweet said, “This government provides encouragement and pride to Ayurveda. The communication gap has been done away with and we have 100% fulfilled all standard parameters for Randomised Placebo-Controlled Clinical Trials. We’ve given information for the same to Ministry of AYUSH.”

Yoga Guru Baba Ramdev’s ayurvedic brand Patanjali unveiled on Tuesday, what he calls, the first ayurvedic medicine against the coronavirus. The Corona kit will be made available at just Rs 545, said Acharya Balkrishna, chief executive officer of Patanjali, adding that the kit is for 30 days. Yoga Guru Ramdev said at a press conference in Hairdwar said that the new drugs ‘coronil’ has shown 100 per cent recovery rate within 3-7 days. After which Ministry of AYUSH requested concerned State Licensing Authority of Uttrakhand Government to provide copies of license and product approval details of the Ayurvedic medicines being claimed for the treatment of COVID -19.

Meanwhile, Baba Ramdev has also announced that a new app “OrderMe” through which people will be able to order ‘Coronil’ by sitting at home. The app “OrderMe” for users is likely to go live very soon.

Also Read: Govt seeks facts of claim made by Patanjali about its COVID-19 drugs, bans advertisements

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

error: Content is protected !!
Close
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker